Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Operating Income of -$9.95 million for fiscal year 2025.
BRAINSTORM CELL THERAPEUTICS INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$9.95M | +14.9% |
| 2024 | -$11.69M | +45.5% |
| 2023 | -$21.44M | +13.6% |
| 2022 | -$24.82M | -1.2% |
| 2021 | -$24.54M | +22.6% |
| 2020 | -$31.68M | -37.8% |
| 2019 | -$23.00M | -63.6% |
| 2018 | -$14.06M | -181.3% |
| 2017 | -$5.00M | +1.7% |
| 2016 | -$5.08M | +40.5% |
| 2015 | -$8.54M | -15.0% |
| 2014 | -$7.42M | -51.5% |
| 2013 | -$4.90M | -43.0% |
| 2012 | -$3.42M | +12.5% |
| 2011 | -$3.91M | -263.0% |
| 2010 | $2.40M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.05M | +32.8% | +20.4% |
| June 30, 2025 | -$2.57M | +13.7% | +16.7% |
| March 31, 2025 | -$3.09M | -24.9% | -1.3% |
| September 30, 2024 | -$3.05M | +49.5% | -2.2% |
| June 30, 2024 | -$2.98M | +45.3% | -20.5% |
| March 31, 2024 | -$2.47M | +52.0% | +59.0% |
| September 30, 2023 | -$6.04M | +11.8% | -10.8% |
| June 30, 2023 | -$5.45M | +28.2% | -5.8% |
- BRAINSTORM CELL THERAPEUTICS INC. showed an increase of +14.9% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, BRAINSTORM CELL THERAPEUTICS INC.’s operating income has declined by 514.7% (from $2.40 million to -$9.95 million).
- The most recent figure is from BRAINSTORM CELL THERAPEUTICS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: